<DOC>
	<DOCNO>NCT01973049</DOCNO>
	<brief_summary>To demonstrate effectiveness DCV 3DAA fix dose combination without Ribavirin treatment naive cirrhotic subject .</brief_summary>
	<brief_title>UNITY 2 : A Study Investigational Treatment Regimen DCV+ASV+BMS-791325 Fixed Dose Combination ( DCV 3DAA ( Direct Acting Antiviral ) Regimen ) With Without RBV 12 Weeks Treatment Chronic Hepatitis C Virus ( HCV ) Genotype 1 Infection Subjects With Compensated Cirrhosis</brief_title>
	<detailed_description>Masking Double blind RBV : two party unaware intervention assignment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects chronically infect HCV genotype 1 Subjects compensate cirrhosis HCV RNA ≥ 10,000 IU/mL screen Treatmentnaïve subject previous exposure interferon formulation ( ie , IFNα , pegIFNα ) , Ribavirin ( RBV ) , HCV Direct Acting Antivirals ( DAA ) ( protease , polymerase inhibitor , etc . ) Treatmentexperienced subject eligible include exposure antiHCV agent mechanistic class contain Daclatasvir ( DCV ) / Asunaprevir ( ASV ) /BMS791325 triple regimen permit . Examples permit agent include , limited nucleoside/nucleotide inhibitor nonstructural protein 5B ( NS5B ) polymerase , inhibitor cyclophilin , inhibitor microRNA . Subjects without cirrhosis Liver organ transplant Current known history cancer within 5 year prior screen Documented suspect hepatocellular carcinoma ( HCC ) Evidence decompensated liver disease include , limited , radiologic criterion , history presence ascites , bleed varix , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>